Decision-making tool to help women with early breast cancer choose treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The team will develop a patient decision aid (PDA) with input from patients, surgeons, oncologists, psychologists, radiologists, and nurses and then test its use at the European Institute of Oncology in Milan. The work has two prospective components: semi-structured interviews with previously treated patients and a prospective component where newly diagnosed patients are assigned to a PDA or a control group and complete online questionnaires at T0 (one week), T1 (one month), and T2 (three months) after the first consultation. About 170 patients and 30 clinicians will be involved, and measures will include patient knowledge, doctor–patient communication, symptom management, and hospital economic indicators. The project uses a patient-centered, data-driven design process with active patient participation from design through dissemination.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* be 18 or older;
* have received/receive diagnosis of resectable breast cancer in the early stage;
* women treated or who will undergo oncological treatment for early breast cancer;
* demonstrate the absence of psychopathological features.
* be willing and able to provide written informed consent/assent for the trial

Exclusion Criteria:

* breast cancer patients who showed physical or psychological issues, as well as cognitive impairments that prohibited their participation in this type of study;
* neurological or psychiatric disorders that may compromise the patients' ability to take part in the study.
* Distant metastases from breast cancer or locally advanced/unresectable disease
* Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial

Where it's running

• European Institute of Oncology
  Milan, Italy, Italy Recruiting

Study contacts

• Principal investigator: Gabriella Pravettoni — European Institute of Oncology
• Study coordinator: Gabriella Pravettoni
• Email: gabriella.pravettoni@ieo.it
• Phone: 0039 02 57489731

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using tart cherry juice to prevent nerve damage from chemotherapy in breast cancer patients

  This study is testing if drinking tart cherry juice can help prevent nerve damage in breast cancer patients receiving chemotherapy.

  Recruiting Phase 2 University of California, Davis · Sacramento, California · NCT06268665

• Capecitabine for MRD-positive, resected ER+/HER2-negative breast cancer

  This Phase 2 trial tests whether taking capecitabine can help people with resected, ER-positive/HER2-negative breast cancer who still have molecular residual disease after standard therapy.

  Recruiting Phase 2 University Health Network, Toronto · Toronto, Ontario · NCT07631052

• Adding TheraBionic P1 radiofrequency therapy to treatment for early-stage HR+ HER2- breast cancer

  This study will try giving TheraBionic P1 amplitude-modulated radiofrequency therapy before surgery to see if it improves tumor response in women with early-stage, hormone receptor–positive, HER2-negative breast cancer.

  Recruiting at 8 sites Barbara Ann Karmanos Cancer Institute · Clarkston, Michigan and 7 other locations · NCT07218432

• Combining FWD1802 with CDK4/6 inhibitors or everolimus for ER+/HER2- advanced breast cancer

  This trial tests whether adding FWD1802 to CDK4/6 inhibitors or everolimus helps people with ER-positive/HER2-negative unresectable locally advanced or metastatic breast cancer who have progressed on or cannot use standard therapy.

  Recruiting Phase 1/2 Forward Pharmaceuticals Co., Ltd. · Shanghai · NCT07002177

• Using PTFE mesh for breast reconstruction in cancer patients

  This study tests if using a special mesh called PTFE can help women with early-stage breast cancer have better and safer breast reconstruction compared to a traditional method.

  Recruiting Branch Office of "Hadassah Medical Ltd" · Moscow, Skolkovo Innovation Center · NCT06931548

• Predicting how hormone therapy before surgery affects breast cancer

  This study is testing how hormone therapy before surgery can help people with early-stage breast cancer and what it means for their tumors.

  Recruiting Phase 2 George Washington University · Washington D.C., District of Columbia · NCT06806930

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.